The role of thalidomide in myeloma patients eligible for high-dose therapy

被引：0
|
作者：
Cavo, M. [1 ]
机构：
[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol & Med Oncol, Bologna, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：28 / 29
页数：2
相关论文
共 50 条
  • [41] High-dose therapy in multiple myeloma and primary amyloidosis: An overview
    Kyle, RA
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 74 - 83
  • [42] High-dose therapy and innovative approaches to treatment of multiple myeloma
    Barlogie, B
    SEMINARS IN HEMATOLOGY, 2001, 38 (02) : 21 - 27
  • [43] LOW-DOSE THALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Kohei, K. O.
    Ando, S.
    Hasino, S.
    Huse, H.
    Morita, R.
    Takahata, M.
    Onozawa, M.
    Kahata, K.
    Kondo, T.
    Ota, S.
    Kawamura, T.
    Kurosawa, M.
    Aikawa, K.
    Ogawa, T.
    Suzuki, S.
    Takahashi, S.
    Izumiyama, K.
    Iwasaki, H.
    Maemori, M.
    Sakai, H.
    Asaka, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 619 - 620
  • [44] Chemoresistant Myeloma: Phase II Clinical Study with Low-Dose Thalidomide Plus High-Dose Dexamethasone
    Bernardeschi, P.
    Dentico, P.
    Rossi, S.
    Fiorentini, G.
    Giustarini, G.
    Montenora, I.
    Turano, E.
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 90 - 93
  • [45] THROMBOPHILIC ALTERATIONS AND RISK OF VENOUS THROMBOEMBOLISM IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE AND HIGH-DOSE DEXAMETHASONE
    Zamagni, E.
    Valdre, L.
    Cini, M.
    Legnani, C.
    Tosi, P.
    Tacchetti, P.
    Ceccolini, M.
    Patriarca, F.
    Catalano, L.
    Casulli, A. F.
    Volpe, S.
    Perrone, G.
    Masini, L.
    Ledda, A.
    Falcioni, S.
    Brioli, A.
    Gozzetti, A.
    Califano, C.
    Pallotti, M. C.
    Cellini, C.
    Pantani, L.
    Petrucci, A.
    Carubelli, A.
    Baccarani, M.
    Palareti, G.
    Cavo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 363 - 363
  • [46] The role of high-dose chemotherapy in the treatment of multiple myeloma: A controversy
    Kyle, RA
    ANNALS OF ONCOLOGY, 2000, 11 : 55 - 58
  • [47] CR As Major End-Point After Consolidation for Multiple Myeloma Patients Eligible to High Dose Therapy
    Hebraud, Benjamin
    Roussel, Murielle
    Doerr, Gaelle
    Huynh, Anne
    Corre, Jill
    Attal, Michel
    BLOOD, 2011, 118 (21) : 809 - 809
  • [48] CONSOLIDATION THERAPY OF MULTIPLE MYELOMA WITH LOW DOSE THALIDOMIDE AFTER A DOUBLE COURSE OF HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT
    Martino, Massimo
    Morabito, Fortunato
    Irrera, Giuseppe
    Messina, Giuseppe
    Pucci, Giulia
    Console, Giuseppe
    Stelitano, Caterina
    Callea, Vincenzo
    Mamone, Domenico
    Kropp, Maria Grazia
    Iuliano, Franco
    Molica, Stefano
    Iacopino, Pasquale
    ANNALS OF ONCOLOGY, 2004, 15 : 77 - 78
  • [49] Thalidomide/dexamethasone (TD), bortezomib (Velcade)/thalidomide/dexamethasone (VTD) and VBMCP/VBAD/Velcade as induction therapy prior to high-dose therapy/autologous stem cell transplantation in multiple myeloma
    Rosinol, L.
    Cibeira, M. T.
    Martinez, J.
    Mateos, M. V.
    Oriol, A.
    Terol, M. J.
    Garcia-Larana, J.
    Hernandez, D.
    de la Rubia, J.
    Sureda, A.
    Besalduch, J.
    Palomera, L.
    Gonzalez, Y.
    Echebeste, M. A.
    Diaz-Mediavilla, J.
    de Arriba, F.
    Alegre, A.
    Hernandez, M.
    Lahuerta, J. J.
    Miguel, J. F. San
    Blade, J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S18 - S18
  • [50] Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
    Kumar, S
    Gertz, MA
    Dispenzieri, A
    Lacy, MQ
    Wellik, LA
    Fonseca, R
    Lust, JA
    Witzig, TE
    Kyle, RA
    Greipp, PR
    Rajkumar, SV
    BONE MARROW TRANSPLANTATION, 2004, 34 (03) : 235 - 239
12345